...
首页> 外文期刊>Journal of Clinical Pharmacy and Therapeutics >Prochlorperazine tablets repackaged into dose administration aids: can the patient be assured of quality?
【24h】

Prochlorperazine tablets repackaged into dose administration aids: can the patient be assured of quality?

机译:重新包装的丙氯拉嗪片剂制成剂量给药辅助剂:可以确保患者的质量吗?

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND OBJECTIVE: Patients are increasingly requiring their medications to be repackaged into dose administration aids because of the positive outcomes associated with reduction in medication related hospitalization and adverse effects due to improved medicines management. Since the stability of these repackaged medications is not the responsibility of manufacturer, it is important that drug substances with potential stability issues be identified. Thus the objective of this study was to evaluate the stability of prochlorperazine, a light sensitive drug repackaged into dose administration aids (DAAs), in order to provide guidelines to the pharmacist and advice to the patient on appropriate storage. METHODS: Prochlorperazine tablets were stored repackaged in DAAs and in their original packaging for 8 weeks at ambient (25 +/- 1 degrees C; 60 +/- 1.5% RH), accelerated (40 +/- 1 degrees C; 75 +/- 1.5% RH) and in-use conditions encountered in situ both in a pharmacy and the patients' home. They wereassessed for both chemical (using a validated HPLC method) and physical stability according to British Pharmacopoeial (BP) standards. In addition, photostability testing was undertaken under ICH conditions. RESULTS AND DISCUSSION: Chemical and physical stability was confirmed to be within BP Limits. There were, however, noticeable organoleptic changes in the tablets stored under in-use conditions with a progressive grey discolouration over the 8 weeks, starting in week 2. CONCLUSION: Despite the confirmation of physical and chemical stability within BP limits, the discoloration and the potential for photodegradants to cause adverse effects in patients must lead us to draw the conclusion that the quality of this medication has been compromised. Pharmacists thus need to take this into account in repackaging and storage of prochlorperazine in DAAs and advise patients to store their DAA protected from light, heat and humidity.
机译:背景与目的:由于与药物相关的住院治疗减少的积极结果以及药物管理改善带来的不利影响,患者越来越需要将其药物重新包装成剂量辅助剂。由于这些重新包装的药物的稳定性不是制造商的责任,因此重要的是要确定具有潜在稳定性问题的药物。因此,本研究的目的是评估重新包装成剂量辅助剂(DAA)的光敏药物丙氯拉嗪的稳定性,以便为药剂师提供指导并为患者提供适当存储的建议。方法:丙氯拉嗪片剂重新包装在DAA中,并在原始包装中于环境温度(25 +/- 1摄氏度; 60 +/- 1.5%RH)下加速,在40 +/- 1摄氏度; 75 + / -相对湿度为1.5%)和在药房和患者家中都遇到的使用条件。根据英国药典(BP)标准对它们的化学性质(使用经过验证的HPLC方法)和物理稳定性进行了评估。另外,在ICH条件下进行了光稳定性测试。结果与讨论:化学和物理稳定性均在BP限值范围内。但是,在使用条件下,从第2周开始的8周内,片剂在使用状态下会出现明显的感官变化,并逐渐出现灰色变色。结论:尽管已确认在BP限值范围内具有物理和化学稳定性,变色和光降解剂对患者造成不良影响的潜力必须使我们得出结论,该药物的质量已受到损害。因此,药剂师在重新包装和在DAA中储存氯丙嗪时需要考虑到这一点,并建议患者在避光,防热和防潮的情况下存储其DAA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号